Generation of human induced pluripotent stem cells from oral mucosa

Department of Molecular Biology, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto, Tokushima 770-8504, Japan.
Journal of Bioscience and Bioengineering (Impact Factor: 1.88). 09/2010; 110(3):345-50. DOI: 10.1016/j.jbiosc.2010.03.004
Source: PubMed


Induced pluripotent stem (iPS) cells are one of the most promising sources for cell therapy in regenerative medicine. Using a patient's own genetically identical and histocompatible cells is the ideal way to practice personalized regenerative medicine. For personalized iPS cell therapy, the prerequisites for cell source preparation are a simple and safe procedure, no aesthetic or functional damage, and quick wound healing. Oral mucosa fibroblasts (OFs) may have high potential to fulfill these requirements. In this study, biopsy was performed in a dental chair; no significant incisional damage was recognized and rapid wound healing (within a week) was observed. We generated human iPS cells from the isolated OFs via the retroviral gene transfer of OCT4, SOX2, c-MYC, and KLF4. Reprogrammed cells showed ES-like morphology and expressed undifferentiated markers such as OCT4, NANOG, SSEA4, TRA-1-60, and TRA-1-81. Subsequent in vitro and in vivo analyses confirmed the pluripotency of resultant iPS cells, which matched the criteria for iPS cells. In addition, we found that the endogenous expression levels of c-MYC and KLF4 in OFs were similar to those in dermal fibroblasts. Taken together, we propose that OFs could be a practical source for preparing iPS cells to achieve personalized regenerative medicine in the near future.

Download full-text


Available from: Kazuhito Satomura, Oct 14, 2014
58 Reads
  • Source
    • " Downloaded from © International & American Associations for Dental Research 2015 fibroblasts (Miyoshi et al. 2010 "
    [Show abstract] [Hide abstract]
    ABSTRACT: Induced pluripotent stem cells (iPSCs) are the newest member of a growing list of stem cell populations that hold great potential for use in cell-based treatment approaches in the dental field. This review summarizes the dental tissues that have successfully been utilized to generate iPSC lines, as well as the potential uses of iPSCs for tissue regeneration in different dental applications. While iPSCs display great promise in a number of dental applications, there are safety concerns with these cells that need to be addressed before they can be used in clinical settings. This review outlines some of the apprehensions to the use of iPSCs clinically, and it details approaches that are being employed to ensure the safety and efficacy of these cells. One of the major approaches being investigated is the differentiation of iPSCs prior to use in patients. iPSCs have successfully been differentiated into a wide range of cells and tissue types. This review focuses on 2 differentiation approaches-the differentiation of iPSCs into mesenchymal stem cells and the differentiation of iPSCs into osteoprogenitor cells. Both these resulting populations of cells are particularly relevant to the dental field. © International & American Associations for Dental Research 2015.
    Journal of dental research 08/2015; DOI:10.1177/0022034515599769 · 4.14 Impact Factor
  • Source
    • "Successful reprogramming also quickly translated to a wide variety of other cell types, including pancreatic β-cells (Stadtfeld et al., 2008), neural stem cells (Eminli et al., 2008) mature B cells (Hanna et al., 2008), stomach and liver cells (Aoi et al., 2008), melanocytes (Utikal et al., 2009), adipose stem cells (Sun et al., 2009), and keratinocytes (Maherali and Hochedlinger, 2008), demonstrating a universal capacity to alter cellular identity . In dentistry, iPS cells have been generated from many types of dental tissues/cells, including SHEDs, SCAPs, DPSCs, tooth germ progenitor cells (TGPCs), buccal mucosa fibroblasts, gingival fibroblasts, and periodontal ligament fibroblasts (Egusa et al., 2010; Miyoshi et al., 2010; Oda et al., 2010; Tamaoki et al., 2010; Yan et al., 2010; Wada et al., 2011). DPSCs show much higher reprogramming efficiency than the conventionally used dermal fibroblasts and high expression of endogenous reprogramming factors such as c-Myc and KLF4 and/or ESC marker genes (Tamaoki et al., 2010). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells are capable of renewing themselves through cell division and have the remarkable ability to differentiate into many different types of cells. They therefore have the potential to become a central tool in regenerative medicine. During the last decade, advances in tissue engineering and stem cell-based tooth regeneration have provided realistic and attractive means of replacing lost or damaged teeth. Investigation of embryonic and adult (tissue) stem cells as potential cell sources for tooth regeneration has led to many promising results. However, technical and ethical issues have hindered the availability of these cells for clinical application. The recent discovery of induced pluripotent stem (iPS) cells has provided the possibility to revolutionize the field of regenerative medicine (dentistry) by offering the option of autologous transplantation. In this article, we review the current progress in the field of stem cell-based tooth regeneration and discuss the possibility of using iPS cells for this purpose.
    Frontiers in Physiology 02/2014; 5:36. DOI:10.3389/fphys.2014.00036 · 3.53 Impact Factor
  • Source
    • "Similarly, Yu and colleagues generated human induced pluripotent stem cells (hiPSCs) based on lentiviral transfer of OCT4, SOX2, LIN28, and NANOG [2]. Reprogramming has now been performed and tested with numerous somatic sources, displaying a range of kinetics and efficiencies [4], including accessible sources such as keratinocytes from skin [5], peripheral blood [6-8], mesenchymal cells in fat [9], epithelial cells in urine [10,11], and oral mucosa [12]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Heart diseases remain a major cause of mortality and morbidity worldwide. However, terminally differentiated human adult cardiomyocytes (CMs) possess a very limited innate ability to regenerate. Directed differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) into CMs has enabled clinicians and researchers to pursue the novel therapeutic paradigm of cell-based cardiac regeneration. In addition to tissue engineering and transplantation studies, the need for functional CMs has also prompted researchers to explore molecular pathways and develop strategies to improve the quality, purity and quantity of hESC-derived and iPSC-derived CMs. In this review, we describe various approaches in directed CM differentiation and driven maturation, and discuss potential limitations associated with hESCs and iPSCs, with an emphasis on the role of epigenetic regulation and chromatin remodeling, in the context of the potential and challenges of using hESC-CMs and iPSC-CMs for drug discovery and toxicity screening, disease modeling, and clinical applications.
    Stem Cell Research & Therapy 08/2013; 4(4):97. DOI:10.1186/scrt308 · 3.37 Impact Factor
Show more